on major coronary events in hypercholesterolaemic patients (JELIS): a Shirato K; Japan EPA lipid intervention study (JELIS) Investigators. Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded. Significant reduction in residual risk in patients treated with statins. Results from the JELIS (Japan EPA Lipid Intervention Study) trial. EPA may have beneficial.

Author: Gardale Dikora
Country: Saudi Arabia
Language: English (Spanish)
Genre: Medical
Published (Last): 20 August 2008
Pages: 360
PDF File Size: 2.36 Mb
ePub File Size: 13.27 Mb
ISBN: 765-5-25278-249-7
Downloads: 33011
Price: Free* [*Free Regsitration Required]
Uploader: Kigara

Serum LDL cholesterol was not a significant factor in a reduction of risk for major coronary events. The primary endpoint was any major coronary event, including sudden cardiac death, fatal and non-fatal myocardial infarction, and other non-fatal events including unstable angina pectoris, angioplasty, stenting, or coronary artery bypass grafting.

These stydy suggest that at least some of the impact of VASCEPA on the reduction in ischemic events may be explained by metabolic effects other than triglyceride lowering. Regarding prior diagnoses of cardiovascular disease, Incremental effects of eicosapentaenoic acid on cardiovascular events in statin-treated patients with coronary artery disease.

We encourage you to check that for yourself. The median change in LDL-C was 3.

EPA is a promising treatment for prevention of major coronary events, and especially non-fatal coronary events, in Japanese hypercholesterolaemic patients. The trial population was Nat Clin Pract Cardiovasc Med. No head-to-head cardiovascular outcomes study of EPA vs a mixture of omega-3 acids has been conducted. United States Food and Drug Administration et al.

  DIN EN ISO 6270-2 PDF

The Kaplan-Meier estimates of the cumulative incidence of the primary and key secondary composite endpoints over time are shown in Figure 1 and Figure 2 below. The median follow-up duration was 58 months 4. In patients with severe hypertriglyceridemia, the effect of VASCEPA on cardiovascular mortality or morbidity or on the risk of pancreatitis has not been determined. Sudden cardiac death and coronary death did not differ between groups. This focus includes a commitment to research and education in cardiovascular health.

Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia [published online ahead of print November 10, ]. We aimed to test the hypothesis that long-term use of eicosapentaenoic acid EPA is effective for prevention of major coronary events in hypercholesterolaemic patients in Japan who consume a large amount of fish. Further detailed data assessment by Amarin and regulatory authorities will continue and take several months to complete and record The final evaluation of the totality of the efficacy and safety data from REDUCE-IT may include some or all of the following, as well as other considerations: Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: While the DMC noted variation in LDL-C measurements in both arms and that a small physiological effect of mineral oil might be possible, the DMC concluded that it was not possible to determine if the LDL-C increase in the placebo arm was a natural increase over time or due to the mineral oil, they found no apparent effect on outcomes and found that this small change was unlikely to explain the observed benefit of VASCEPA over placebo.


About Amarin

Yes No By clicking yes, you are certifying you are also a US resident. Am J Cardiovasc Drugs. On stable background lipid-lowering therapy, the median [Q1, Q3] fasting TG was Eligible patients include those who participate in commercial insurance, through a healthcare exchange, or pay cash.

Not for use by residents of VT, nor medical professionals licensed in VT.

VASCEPA® (icosapent ethyl) | REDUCE-IT™ Results Announced

Adverse events and serious adverse events leading to study drug discontinuation were similar to placebo. Adapted from Yokoyama et al, Figure 3: Patients were randomly assigned 1: Overall adverse event rates were similar across treatment groups.

Curves were visually truncated at 5. This information on inflammatory markers cannot be used in isolation. Most patients at baseline were taking at least one other cardiovascular medication including anti-platelet agents The median age at baseline was 64 years range: Other cardiovascular outcomes trials that studied fish oil or mixtures of omega-3 acids that include the omega-3 acid, DHA, have reported negligible impact on cardiovascular events.

Overview of prescription omega-3 fatty acid products for hypertriglyceridemia. P values for Lp-PLA 2a secondary endpoint, were adjusted for multiple comparisons; all other endpoints are exploratory.

Effects of EPA on coronary artery disease in hypercholesterolemic patients with multiple risk factors: The study was studyy at ClinicalTrials. Watch the national commercial.